Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to ...

Despite major advances in targeted therapies, immunotherapies, and combination regimens, therapy resistance remains a central barrier to durable cancer ...

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized oncology. However, a significant proportion of patients ...

Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...

Sleep deprivation has long been known to weaken the immune system. Now UF Health Cancer Institute researchers have made a ...

The stroma to tumor ratio potentially identifies higher risk bladder cancer tumors and might help guide immunotherapy. Bladder tumors with higher stromal content may have a more immunosuppressive ...

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be ...

Questions about antioxidants and cancer rarely stay simple. Antioxidants are usually framed as protective substances that ...